Joseph Coyle

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior
    A C Basu
    Department of Psychiatry, Harvard Medical School, Belmont, MA 02478, USA
    Mol Psychiatry 14:719-27. 2009
  2. pmc NMDA receptor and schizophrenia: a brief history
    Joseph T Coyle
    Department of Psychiatry and Neuroscience, Harvard Medical School, McLean Hospital, Belmont, MA, USA
    Schizophr Bull 38:920-6. 2012
  3. ncbi request reprint Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms
    Joseph T Coyle
    Harvard Medical School, Department of Psychiatry, McLean Hospital, Belmont, MA 02478, USA
    Neurotox Res 10:221-33. 2006
  4. ncbi request reprint Finding the intracellular signaling pathways affected by mood disorder treatments
    Joseph T Coyle
    Harvard Medical School, Department of Psychiatry, McLean Hospital, Belmont, MA 02478, USA
    Neuron 38:157-60. 2003
  5. ncbi request reprint Ionotropic glutamate receptors as therapeutic targets in schizophrenia
    Joseph T Coyle
    Curr Drug Targets CNS Neurol Disord 1:183-9. 2002
  6. ncbi request reprint A brief overview of N-acetylaspartate and N-acetylaspartylglutamate
    Joseph T Coyle
    Department of Psychiatry and Neuroscience, Harvard Medical School, McLean Hospital, 115 Mill St, Belmont, MA 02178 9106, USA
    Adv Exp Med Biol 576:1-6; discussion 361-3. 2006
  7. ncbi request reprint Glutamate and schizophrenia: beyond the dopamine hypothesis
    Joseph T Coyle
    Harvard Medical School, McLean Hospital, Belmont, Masschusetts 02478, USA
    Cell Mol Neurobiol 26:365-84. 2006
  8. ncbi request reprint Glial metabolites of tryptophan and excitotoxicity: coming unglued
    Joseph T Coyle
    Department of Psychiatry, Harvard Medical School, McLean Hospital, 115 Mill St, Belmont, MA 02478, USA
    Exp Neurol 197:4-7. 2006
  9. ncbi request reprint Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia
    Joseph T Coyle
    McLean Hospital, Belmont, Massachusetts 02478, USA
    Ann N Y Acad Sci 1003:318-27. 2003
  10. ncbi request reprint The GABA-glutamate connection in schizophrenia: which is the proximate cause?
    Joseph T Coyle
    Department of Psychiatry, Harvard Medical School, McLean Hospital, 115 Mill St, Belmont, MA 02478, USA
    Biochem Pharmacol 68:1507-14. 2004

Research Grants

  1. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph Coyle; Fiscal Year: 2001
  2. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph Coyle; Fiscal Year: 2005
  3. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph Coyle; Fiscal Year: 2000
  4. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph Coyle; Fiscal Year: 2009
  5. Computational Core
    Joseph Coyle; Fiscal Year: 2007
  6. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph Coyle; Fiscal Year: 2007
  7. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph Coyle; Fiscal Year: 2006
  8. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph Coyle; Fiscal Year: 2002
  9. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph T Coyle; Fiscal Year: 2011

Collaborators

Detail Information

Publications45

  1. pmc Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior
    A C Basu
    Department of Psychiatry, Harvard Medical School, Belmont, MA 02478, USA
    Mol Psychiatry 14:719-27. 2009
    ....
  2. pmc NMDA receptor and schizophrenia: a brief history
    Joseph T Coyle
    Department of Psychiatry and Neuroscience, Harvard Medical School, McLean Hospital, Belmont, MA, USA
    Schizophr Bull 38:920-6. 2012
    ....
  3. ncbi request reprint Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms
    Joseph T Coyle
    Harvard Medical School, Department of Psychiatry, McLean Hospital, Belmont, MA 02478, USA
    Neurotox Res 10:221-33. 2006
    ..Given the role of NMDA receptors in the reward circuitry and in substance dependence, it is reasonable to speculate that NMDA receptor dysfunction is a shared pathologic process in schizophrenia and co-morbid SUDs...
  4. ncbi request reprint Finding the intracellular signaling pathways affected by mood disorder treatments
    Joseph T Coyle
    Harvard Medical School, Department of Psychiatry, McLean Hospital, Belmont, MA 02478, USA
    Neuron 38:157-60. 2003
    ..These insights should assist in understanding the pathophysiology of severe mood disorders as well as aid in the development of more effective treatments...
  5. ncbi request reprint Ionotropic glutamate receptors as therapeutic targets in schizophrenia
    Joseph T Coyle
    Curr Drug Targets CNS Neurol Disord 1:183-9. 2002
    ..Preliminary results with an allosteric modulator of the AMPA subtype of glutamate receptor suggest enhanced cognitive functions in subjects treated with clozapine...
  6. ncbi request reprint A brief overview of N-acetylaspartate and N-acetylaspartylglutamate
    Joseph T Coyle
    Department of Psychiatry and Neuroscience, Harvard Medical School, McLean Hospital, 115 Mill St, Belmont, MA 02178 9106, USA
    Adv Exp Med Biol 576:1-6; discussion 361-3. 2006
  7. ncbi request reprint Glutamate and schizophrenia: beyond the dopamine hypothesis
    Joseph T Coyle
    Harvard Medical School, McLean Hospital, Belmont, Masschusetts 02478, USA
    Cell Mol Neurobiol 26:365-84. 2006
    ..5. Thus, hypofunction of the NMDA receptor, possibly on critical GABAergic inter-neurons, may contribute to the pathophysiology of schizophrenia...
  8. ncbi request reprint Glial metabolites of tryptophan and excitotoxicity: coming unglued
    Joseph T Coyle
    Department of Psychiatry, Harvard Medical School, McLean Hospital, 115 Mill St, Belmont, MA 02478, USA
    Exp Neurol 197:4-7. 2006
  9. ncbi request reprint Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia
    Joseph T Coyle
    McLean Hospital, Belmont, Massachusetts 02478, USA
    Ann N Y Acad Sci 1003:318-27. 2003
    ..Thus, there is convincing evidence that hypofunction of a subset of NMDA receptors may contribute to the symptomatic features of schizophrenia...
  10. ncbi request reprint The GABA-glutamate connection in schizophrenia: which is the proximate cause?
    Joseph T Coyle
    Department of Psychiatry, Harvard Medical School, McLean Hospital, 115 Mill St, Belmont, MA 02478, USA
    Biochem Pharmacol 68:1507-14. 2004
    ..Electrophysiologic and pharmacologic studies suggest that the vulnerable NMDA receptors in schizophrenia may be concentrated on cortico-limbic GABAergic interneurons, thereby linking these two neuropathologic features of the disorder...
  11. ncbi request reprint The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia
    Joseph T Coyle
    Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA 02478, USA
    Psychopharmacology (Berl) 174:32-8. 2004
    ..Thus, there is convincing evidence that the glycine modulatory site on the NMDA receptor is a valid therapeutic target for improving cognition and associated negative symptoms in schizophrenia...
  12. pmc What can a clock mutation in mice tell us about bipolar disorder?
    Joseph T Coyle
    Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA
    Proc Natl Acad Sci U S A 104:6097-8. 2007
  13. pmc Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia
    Joseph T Coyle
    Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA 02478, USA
    Dialogues Clin Neurosci 12:359-82. 2010
    ..Potential sites for pharmacologic intervention targeting glutatatergic, GABAergic, and cholinergic neurotransmission to treat these symptoms of schizophrenia are discussed...
  14. ncbi request reprint Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology
    Joseph T Coyle
    Department of Psychiatry, Harvard Medical School, Belmont, MA 02478, USA
    J Alzheimers Dis 11:491-507. 2007
    ..The use of nAChR agonists and antagonists in some of these studies lends support to the proposed allosteric potentiating ligand activity of galantamine at nAChRs. This dual action of galantamine may account for its therapeutic profile...
  15. ncbi request reprint Folate, homocysteine, and negative symptoms in schizophrenia
    Donald C Goff
    Schizophrenia Program and Neurology Service, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 161:1705-8. 2004
    ....
  16. ncbi request reprint D-cycloserine added to clozapine for patients with schizophrenia
    D C Goff
    Psychotic Disorders Program, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 153:1628-30. 1996
    ..The effects of D-cycloserine added to clozapine were assessed and compared with previous results for D-cycloserine plus conventional neuroleptics...
  17. ncbi request reprint The nagging question of the function of N-acetylaspartylglutamate
    J T Coyle
    Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts 02178, USA
    Neurobiol Dis 4:231-8. 1997
    ..The levels of NAAG and the activity of carboxypeptidase II are altered in a regionally specific fashion in several neuropsychiatric disorders...
  18. ncbi request reprint Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal
    G E Tsai
    Department of Psychiatry, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 155:726-32. 1998
    ..Whether glutamatergic neurotransmission and oxidative stress are enhanced during ethanol withdrawal in humans is unknown...
  19. ncbi request reprint A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia
    D C Goff
    Massachusetts General Hospital, Harvard Consolidated Department of Psychiatry, Boston, USA
    Arch Gen Psychiatry 56:21-7. 1999
    ....
  20. ncbi request reprint Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment
    G E Tsai
    Geriatric Neurobehavoral Clinic, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, USA
    Am J Psychiatry 156:467-9. 1999
    ..D-Cycloserine exhibits partial agonist activity at the glycine site of N-methyl-D-aspartate subtype glutamate receptor, facilitating activation of the receptor and improving cognition and memory...
  21. ncbi request reprint D-serine added to clozapine for the treatment of schizophrenia
    G E Tsai
    Laboratory of Molecular and Psychiatric Neuroscience, Mailman Research Center, McLean Hospital, Belmont, MA 02478, USA
    Am J Psychiatry 156:1822-5. 1999
    ..To study the difference between full and partial agonists at the NMDA receptor glycine site, the clinical effects of adding D-serine to clozapine were assessed...
  22. ncbi request reprint Evidence for the presence of N-acetylaspartylglutamate in cultured oligodendrocytes and LPS activated microglia
    L Passani
    Laboratory of Molecular and Developmental Neuroscience, Massachusetts General Hospital, Charlestown, MA 02129, USA
    Brain Res 794:143-5. 1998
    ..The findings indicate that NAAG is localized to specific glial cell types. Further our results suggest that NAAG biosynthesis is induced in microglia, activated by specific stimuli...
  23. ncbi request reprint Modeling of context-dependent retrieval in hippocampal region CA1: implications for cognitive function in schizophrenia
    Peter J Siekmeier
    Department of Psychiatry, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA
    Schizophr Res 89:177-90. 2007
    ..As such, it can shed light on the etiology of schizophrenia in a fundamental way, and also holds the promise of pointing the way to more effective treatments...
  24. pmc Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II
    R Luthi-Carter
    Department of Psychiatry, Massachusetts General Hospital East, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 95:3215-20. 1998
    ....
  25. pmc Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase
    R E Carter
    Department of Psychiatry, Massachusetts General Hospital East, Charlestown 02129, USA
    Proc Natl Acad Sci U S A 93:749-53. 1996
    ..These results also raise questions about the role of PSM in both normal and pathologic prostate epithelial-cell function...
  26. ncbi request reprint Early embryonic death of glutamate carboxypeptidase II (NAALADase) homozygous mutants
    G Tsai
    Laboratory of Molecular and Psychiatric Neuroscience, Mailman Research Center, McLean Hospital Department of Psychiatry, Harvard Medical School, Cambridge, Massachusetts, USA
    Synapse 50:285-92. 2003
    ..The results indicate that the expression of glutamate carboxypeptidase II is upregulated when one allele is inactivated and that its activity is essential for early embryogenesis...
  27. ncbi request reprint NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia
    Joseph T Coyle
    Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts, USA
    Int Rev Neurobiol 59:491-515. 2004
  28. ncbi request reprint L-type calcium channels reduce ROS generation in cerebellar granule cells following kainate exposure
    Michael L Leski
    Laboratory of Molecular Neuroscience, McLean Hospital, Belmont, Massachusetts 02178, USA
    Synapse 43:30-41. 2002
    ....
  29. pmc Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia
    John E Lisman
    Department of Biology, Brandeis University, 415 South Street, Waltham, MA 02454, USA
    Trends Neurosci 31:234-42. 2008
    ..iii) Nicotine enhances the output of interneurons, and might thereby contribute to its therapeutic effect in schizophrenia...
  30. pmc Ube3a mRNA and protein expression are not decreased in Mecp2R168X mutant mice
    Amy Lawson-Yuen
    Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA 02478, USA
    Brain Res 1180:1-6. 2007
    ..The male mice experience early death. Analysis of Ube3a mRNA and protein levels in the Mecp2(R168X) male mice showed no significant difference in expression compared to their wild type littermates...
  31. pmc Gene knockout of glycine transporter 1: characterization of the behavioral phenotype
    Guochuan Tsai
    Department of Psychiatry and Alcohol and Drug Abuse Research Center, McLean Hospital, Belmont, MA 02178, USA
    Proc Natl Acad Sci U S A 101:8485-90. 2004
    ....
  32. ncbi request reprint Glutamatergic mechanisms in schizophrenia
    Guochuan Tsai
    Laboratory of Molecular and Psychiatric Neuroscience, Mailman Research Center, Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts 02478, USA
    Annu Rev Pharmacol Toxicol 42:165-79. 2002
    ..Thus, hypofunction of a subpopulation of cortico-limbic NMDA receptors may participate in the pathophysiology of schizophrenia...
  33. ncbi request reprint Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus
    Richard Bergeron
    Ottawa Health Research Institute, Department of Psychiatry, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
    J Neurochem 100:346-57. 2007
    ..All together, these results suggest that NAAG acts as an endogenous modulator of NMDARs in the CA1 area of the hippocampus...
  34. ncbi request reprint Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine
    Cecilia Flores
    Department of Psychiatry, Harvard Medical School and McLean Hospital, Mailman Research Center, Belmont, MA, USA
    Neuropsychopharmacology 28:1227-34. 2003
    ..These results demonstrate that psychotomimetic and neuroleptic drugs modulate GCP II function in brain regions that are widely involved in the neuropathology of schizophrenia...
  35. ncbi request reprint NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons
    Richard Bergeron
    Ottawa Health Research Institute, Ottawa, ON, Canada
    Neuropsychopharmacology 30:7-16. 2005
    ..Moreover, in dissociated pyramidal neurons of the CA1 region, NAAG also reduced the NMDA current and this effect was reversed by glycine. These results suggest that NAAG reduces the NMDA currents in hippocampal CA1 pyramidal neurons...
  36. ncbi request reprint Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia
    Subroto Ghose
    Clinical Brain Disorders Branch, IRP, NIMH, NIH, Bethesda, MD 20892, USA
    Neuropsychopharmacology 29:117-25. 2004
    ..Our findings support the notion that the hydrolysis of NAAG is disrupted in schizophrenia and that specific anatomical regions may show discrete abnormalities in GCP II synthesis...
  37. pmc Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice
    Marzia Martina
    Departments of Cellular and Molecular Medicine, and Psychiatry, University of Ottawa, Ottawa, ON, Canada
    J Physiol 563:777-93. 2005
    ..Overall, these findings highlight the importance of GlyT1 in regulating glutamatergic neurotransmission...
  38. ncbi request reprint Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine
    Deborah A Yurgelun-Todd
    Cognitive Neuroimaging Laboratory, Brain Imaging Center, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA
    Psychiatry Res 138:23-31. 2005
    ..These results suggest that the addition of D-cycloserine to conventional neuroleptics may improve negative symptoms through enhanced temporal lobe function...
  39. ncbi request reprint Do maternal folate and homocysteine levels play a role in neurodevelopmental processes that increase risk for schizophrenia?
    Jonathan D Picker
    Department of Genetics, Harvard Medical School McLean Hospital, Belmont, MA, USA
    Harv Rev Psychiatry 13:197-205. 2005
    ....
  40. ncbi request reprint Decoding schizophrenia
    Daniel C Javitt
    Program in Cognitive Neuroscience and Schizophrenia, Nathan Kline Institute, Orangeburg, N Y, USA
    Sci Am 290:48-55. 2004
  41. ncbi request reprint Low cerebrospinal fluid glutamate and glycine in refractory affective disorder
    Mark A Frye
    Department of Psychiatry, University of California Los Angeles Neuropsychiatric Institute, Los Angeles, CA, USA
    Biol Psychiatry 61:162-6. 2007
    ..Glutamatergic dysregulation has been documented in schizophrenia but has received less systematic study in affective illness...
  42. ncbi request reprint Depression and bipolar support alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in children and adolescents
    Joseph T Coyle
    J Am Acad Child Adolesc Psychiatry 42:1494-503. 2003
    ..To focus attention on the critical unmet needs of children and adolescents with mood disorders and to make recommendations for future research and allocation of healthcare resources...
  43. ncbi request reprint Treating a child with Asperger's disorder and comorbid bipolar disorder
    Jean A Frazier
    Department of Psychiatry, Harvard Medical School, Boston, MA, USA
    Am J Psychiatry 159:13-21. 2002
  44. ncbi request reprint Getting balance: drugs for bipolar disorder share target
    Joseph T Coyle
    Nat Med 8:557-8. 2002
  45. ncbi request reprint Neurobiology of schizophrenia
    Christopher A Ross
    Division of Neurobiology, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Neuron 52:139-53. 2006
    ..Understanding these basic pathologic processes may yield novel targets for the development of more effective treatments...

Research Grants12

  1. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph Coyle; Fiscal Year: 2001
    ..These studies should further clarify the role of NAAG in modulating brain glutamatergic neurotransmission that should have significant implications for neurodegenerative disorders, schizophrenia and epilepsy. ..
  2. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph Coyle; Fiscal Year: 2005
    ..Findings from these studies should shed light on the pathophysiology of schizophrenia and may identify potential strategies for novel treatments. ..
  3. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph Coyle; Fiscal Year: 2000
    ..These studies should further clarify the role of NAAG in modulating brain glutamatergic neurotransmission that should have significant implications for neurodegenerative disorders, schizophrenia and epilepsy. ..
  4. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph Coyle; Fiscal Year: 2009
    ..Findings from these studies should shed light on the pathophysiology of schizophrenia and may identify potential strategies for novel treatments. ..
  5. Computational Core
    Joseph Coyle; Fiscal Year: 2007
    ..abstract_text> ..
  6. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph Coyle; Fiscal Year: 2007
    ..Findings from these studies should shed light on the pathophysiology of schizophrenia and may identify potential strategies for novel treatments. ..
  7. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph Coyle; Fiscal Year: 2006
    ..Findings from these studies should shed light on the pathophysiology of schizophrenia and may identify potential strategies for novel treatments. ..
  8. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph Coyle; Fiscal Year: 2002
    ..These studies should further clarify the role of NAAG in modulating brain glutamatergic neurotransmission that should have significant implications for neurodegenerative disorders, schizophrenia and epilepsy. ..
  9. PSYCHOSIS AND BRAIN GLUTAMATE
    Joseph T Coyle; Fiscal Year: 2011
    ..He will use the model to clarify the underlying mechanisms, to determine how these mechanisms relate to other schizophrenic risk genes and to test potential treatments to correct these neuronal defects characteristic of schizophrenia. ..